ScreenerHero

KYNBKyntra Bio, Inc.

NAS · US · Healthcare · Biotechnology · kyntrabio.com
7.520USD+5.17%Mkt Cap: 30.45M $P/E: —

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting C…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap30.45M $
Enterprise Value-39.68M $
Revenue (TTM)4.62M $
Gross Profit5.88M $
Net Income (TTM)183.45M $
Revenue/Share1.141 USD
Last Price7.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS31572Q8814
Valuation
P/E (Trailing)—
P/E (Forward)-0.51
PEG—
EV/EBITDA0.79
EV/Revenue-8.60
P/S6.42
P/B-0.68
EPS (TTM)-7.90
EPS (Forward)-14.23
52W Range
6.32019% of range12.60
52W High12.60 USD
52W Low6.320 USD
Profitability
Gross Margin91.37%
Oper. Margin1191.52%
EBITDA Margin0.00%
Profit Margin2848.63%
ROE-610.73%
ROA153.40%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.77M $
CapEx (TTM)38.00K $
FCF Margin1171.46%
FCF Yield177.59%
Net Debt-91.32M $
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity—
Current Ratio2.69
Quick Ratio2.54
Book Value/Sh-10.8210 USD
Cash/Share22.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 17, 2025
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.00 USD
Upside (mean)+418.6%
Target Range35.00 USD – 43.00 USD
$35.00+418.6% to mean$43.00
# Analysts2
Ownership
Shares Out.4.05M
Float3.56M
Insiders2.02%
Institutions24.68%
Short Interest
Short Ratio9.1d
Short % Float2.46%
Short % Out.2.41%
Shares Short97.56K
Short (prev mo.)109.51K
Technical
SMA 507.102 (+5.9%)
SMA 2007.699 (-2.3%)
Beta1.04
S&P 52W Chg18.16%
Avg Vol (30d)9.81K
Avg Vol (10d)12.97K
Technical Indicators
RSI (14)61.0
MACD0.0198
MACD Signal-0.0224
MACD Hist.+0.0422
BB Upper7.376 USD
BB Middle7.003 USD
BB Lower6.630 USD
BB Width10.65%
ATR (14)0.2959 USD
Vol Ratio (20d)5.17x